← Back to Screener
Foghorn Therapeutics Inc. Common Stock (FHTX)
Price$4.86
Favorite Metrics
Price vs S&P 500 (26W)4.24%
Price vs S&P 500 (4W)-6.03%
Market Capitalization$285.87M
All Metrics
Book Value / Share (Quarterly)$0.00
P/TBV (Annual)1643.45x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)17.14%
Cash Flow / Share (Quarterly)$-1.52
Price vs S&P 500 (YTD)-12.46%
Net Profit Margin (TTM)-240.33%
EPS (TTM)$-1.18
10-Day Avg Trading Volume0.14M
EPS Excl Extra (TTM)$-1.18
Revenue Growth (5Y)135.14%
EPS (Annual)$-1.18
ROI (Annual)-108880.00%
Net Profit Margin (5Y Avg)-1830.74%
Cash / Share (Quarterly)$2.80
Revenue Growth QoQ (YoY)223.77%
ROA (Last FY)-37.50%
Revenue Growth TTM (YoY)36.75%
EBITD / Share (TTM)$-1.27
Operating Margin (TTM)-279.49%
Cash Flow / Share (Annual)$-1.52
P/B Ratio2858.70x
P/B Ratio (Quarterly)2666.96x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)6.63x
Net Interest Coverage (TTM)-52.05x
ROA (TTM)-33.46%
EPS Incl Extra (Annual)$-1.18
Current Ratio (Annual)2.73x
Quick Ratio (Quarterly)2.68x
3-Month Avg Trading Volume0.17M
52-Week Price Return35.65%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-1.36
P/S Ratio (Annual)9.25x
Asset Turnover (Annual)0.16x
52-Week High$6.95
Operating Margin (5Y Avg)-1876.78%
EPS Excl Extra (Annual)$-1.18
CapEx CAGR (5Y)-68.53%
26-Week Price Return8.22%
Quick Ratio (Annual)2.68x
13-Week Price Return-23.67%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.73x
Enterprise Value$204.994
Revenue / Share Growth (5Y)111.13%
Asset Turnover (TTM)0.14x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-240.33%
Cash / Share (Annual)$2.80
3-Month Return Std Dev77.30%
Net Income / Employee (TTM)$-1
ROE (Last FY)-108880.00%
Net Interest Coverage (Annual)-51.77x
EPS Basic Excl Extra (Annual)$-1.18
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.18
Receivables Turnover (Annual)0.13x
ROI (TTM)-301.61%
P/S Ratio (TTM)9.25x
Pretax Margin (5Y Avg)-1828.27%
Revenue / Share (Annual)$0.49
Tangible BV / Share (Annual)$0.00
Price vs S&P 500 (52W)5.82%
Year-to-Date Return-9.81%
5-Day Price Return1.67%
EPS Normalized (Annual)$-1.18
ROA (5Y Avg)-29.76%
Net Profit Margin (Annual)-240.33%
Month-to-Date Return1.88%
Cash Flow / Share (TTM)$-2.38
EBITD / Share (Annual)$-1.27
Operating Margin (Annual)-279.49%
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.18
P/B Ratio (Annual)2666.96x
Pretax Margin (TTM)-240.33%
Book Value / Share (Annual)$0.00
Price vs S&P 500 (13W)-24.36%
Beta3.09x
P/FCF (Annual)1.49x
Revenue / Share (TTM)$0.49
ROE (TTM)-301.61%
52-Week Low$3.26
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.38
4.38
4.38
4.38
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
FHTXFoghorn Therapeutics Inc. Common Stock | 9.25x | 36.75% | — | — | $4.86 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Foghorn Therapeutics discovers and develops medicines targeting dependencies in the chromatin regulatory system using its proprietary Gene Traffic Control platform. The company is advancing two lead candidates—FHD-286, a selective ATPase inhibitor, and FHD-609, a protein degrader—for the treatment of hematologic cancers and solid tumors.